IDEAYA Biosciences IDYA
NASDAQ IDYA
$32.76 +1.01 (+3.18%)
As of: Nov 11, 2026 · 11:23 AM EST

IDEAYA Biosciences (IDYA) Non-Current Deferred Revenue (2020 - 2025)

Updated

IDEAYA Biosciences (IDYA) posted Non-Current Deferred Revenue of $1.68 million for Q3 2025.

Analysis

IDEAYA Biosciences (IDYA) Non-Current Deferred Revenue (2020 - 2025) Analysis & Trends

At the end of FY2022, IDEAYA Biosciences' Non-Current Deferred Revenue came in at $5.19 million, down 83.4% from FY2021.

  • In prior years, IDEAYA Biosciences' Non-Current Deferred Revenue was $31.19 million in FY2021 (-44.5%) and $56.16 million in FY2020.
  • The Q3 2025 figure stands as the highest quarterly Non-Current Deferred Revenue in data going back to Q3 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 IDEAYA Biosciences 3.07 Bn 90.55 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 1.68 Mn
Dec 31, 2022 5.19 Mn
Sep 30, 2022 7.31 Mn
Jun 30, 2022 8.03 Mn
Mar 31, 2022 10.21 Mn
Dec 31, 2021 31.19 Mn
Sep 30, 2021 39.25 Mn
Jun 30, 2021 48.01 Mn
Mar 31, 2021 52.06 Mn
Dec 31, 2020 56.16 Mn
Sep 30, 2020 46.19 Mn
API Access

IDEAYA Biosciences Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=IDYA&period=max&api_key=YOUR_API_KEY